scispace - formally typeset
M

Mitali Chatterjee

Researcher at Bose Corporation

Publications -  213
Citations -  6139

Mitali Chatterjee is an academic researcher from Bose Corporation. The author has contributed to research in topics: Visceral leishmaniasis & Leishmaniasis. The author has an hindex of 43, co-authored 200 publications receiving 5403 citations. Previous affiliations of Mitali Chatterjee include Thomas Jefferson University & Post Graduate Institute of Medical Education and Research.

Papers
More filters
Journal Article

Visceral leishmaniasis - current therapeutic modalities.

TL;DR: Progress made in the treatment of VL is highlighted, including the multiple mechanisms of action of antileishmanial drugs with a view to enable the researcher to undertake the challenge of providing affordable and effective chemotherapy.
Journal ArticleDOI

Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes.

TL;DR: Data indicate that artemisinin has promising anti-leishmanial activity that is mediated by programmed cell death and, accordingly, merits consideration and further investigation as a therapeutic option for the treatment of leishmaniasis.
Journal ArticleDOI

Plant derived therapeutics for the treatment of Leishmaniasis.

TL;DR: An overview of the current status of available leishmanicidal plant derived compounds that are effective singly or in combination with conventional anti-leishmanial drugs, yet are non toxic to mammalian host cells is provided.
Journal ArticleDOI

Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani

TL;DR: A variety of resistance mechanisms to SAG, most of them consistent with a model based on the study of resistance in vitro, were present in clinical isolates from the same geographical region.
Journal ArticleDOI

Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis.

TL;DR: As ROS generated in both peripheral blood and synovial infiltrate correlated positively with both DAS 28 and CRP/anti-CCP levels, its measurement can serve as an indirect measure of the degree of inflammation in patients with RA.